APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
89 Views
Primer: Suzhou Ribo Life Science (6938 HK) - Aug 2026
Suzhou Ribo Life Science is a pioneering Chinese biopharmaceutical company at the forefront of the rapidly growing small interfering RNA...
94 Views
Ribo Life Science (6938 HK): Madrigal MASH Deal A Positive, But Still a Long Waiting Game
Suzhou Ribo Life Science partners with Madrigal Pharmaceuticals for siRNA programs targeting MASH. Upfront payments etc are fine, but Ribo Life is...
235 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
Pre-IPO Suzhou Ribo Life Science (PHIP Updates) - Some Points Worth the Attention
Ribo's IPO pricing (HK$57.97/share) is reasonable and leaves room for valuation increases, thus there is good upside on IPO debut, which is in line...
289 Views